Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. (2016)
Attributed to:
Glasgow Molecular Pathology (GMP) Node
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(16)00380-9
PubMed Identifier: 27197690
Publication URI: http://europepmc.org/abstract/MED/27197690
Type: Journal Article/Review
Volume: 388
Parent Publication: Lancet (London, England)
Issue: 10041
ISSN: 0140-6736